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METABOLIC EFFECTS OF SULFONYLUREAS IN NORMAL MEN 
AND I N  VARIOUS TYPES OF DIABETIC PATIENTS* 
By Stefan S. Fajans, Lawrence H. Louis, Allen R. Hennest, 
Bernard0 L. Wajchenbergt, Robert D. Johnson, Robert D. 
Gittler, Irving P. Ackerman, and Jerome W. Conn 
Metabolism Research Unit of the Division of Endocrinology and Metabolism, Department 
of Internal Medicine, University of Michigan Medical School, A n n  Arbor, Mich. 
The studies described in this report were initiated in an effort to elucidate 
the mechanism of action of the sulfonylurea compounds. It seemed to us 
that a broad clinical investigative approach, involving the study of a large 
number of conditions in which the metabolism of carbohydrate is disturbed, 
was most likely to eliminate quickly a number of possible modeg of action and 
to define more sharply the areas upon which further effort should be concen- 
trated. Thus, extensive metabolic-balance studies and numerous individual 
testing procedures have been performed before, during, and following the 
administration of carbutamide (BZ-55) and/or tolbutamide (Orinasei) in the 
following subjects: (1) healthy young men; (2) three middle-aged, obese, 
stable diabetics; ( 3 )  an unstable diabetic of normal weight; (4) a patient with 
lipo-atrophic diabetes; ( 5 )  a totally depancreatized woman; (6) patients with 
coexisting diabetes mellitus and Addison’s disease, familial diabetes and 
Cushing’s syndrome, and diabetes and panhypopituitarism; and (7) an acro- 
megalic with mild diabetes. 
Although the data reported below do not define a specific mode of action 
of the sulfonylurea compounds, they eliminate from consideration a number 
of important possibilities. 
Results 
Administration of the sulfonylurea compounds to  normal men produces 
definite hypoglycemia. A single dose of either 3 or 6 gm. of tolbutamide 
given to 2 normal subjects in the fasting state produced decreases in blood 
sugar of 35 to 60 per cent. 
In normal subject D. M., administration of 6 gm. of carbutamide as a single 
dose on 2 consecutive days, followed by a dose of 3% and 4 gm. daily in 
divided doses for the next 2 days, produced a fall in the level of fasting blood 
sugar from 78 to 24 mg. per cent (FIGURE 1). Subsequent administration of 
3 gm. daily in divided doses kept levels of fasting blood sugars fairly constant 
at  about 60 mg. per cent. 
In the same normal subjects, when the compounds were administered at  
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FIGIJRE 1. Effect of the administration of carbutamide (BZ-55) on fasting blood sugar 
i n  :I normal whjert. 
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FIGURE 2. Effect of the administration of tolbutamide on fasting blood sugar in a patient 
with diabetes mellitus. 
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FIGUXE 3 .  Effect of tolbutamide on glucose tolerance and hyperglycemia produced by 
glucagon in B diabetic patient. 
the same level of dosage, tolbutamide was less effective than carbutamide in 
reducing the daily fasting blood sugar.' 
FIGURE 2 demonstrates that administration of tolbutamide to a mild dia- 
betic produced a decrease in levels of fasting blood sugar from the hyper- 
glycemic into the normal range. 
Frc,uKrs 3 shows that glucose tolerance was not altered in this patient by 
the administration of tolbutamide for 9 days, even though the fasling 1)lood 
sugar was then in the normal range. Glucose tolerance was also not influ- 
enced significantly during the administration of sulfonylurea compounds to 
healthy individuals.' 
In FIGURE 4 we see that intramuscular administration of adrenalin produced 
the same rise in blood sugar in a normal male, whether given before adminis- 
tration of carbutamide or after the drug had effected a lowering of the blood 
sugar in the fasting state. Similarly, the hyperglycemic response to intra- 
venously administered glucagon was not blocked by administration of these 
drugs in normal subjects,' or in the diabetic patient (FIGURE 3). 
The sulfonylurea drugs did not potentiate the activity of exogenous insulin 
in normal males or in diabetic subjects. 
FIGURE 5 shows the results of insulin tolerance tests performed in a normal 
male. The line 
connecting the open circles shows the blood sugar curve obtained during the 
carbutamide period, but without administration of insulin. Administered 
insulin at  this time was no more effective than it had been before carbutamide 
had produced a hypoglycemic effect, as shown by the line connecting the 
crosses. 
FIGURE 6 shows similar data obtained in a diabetic. The middle curve 
represents the results of a standard insulin tolerance test. The lower 2 curves 
depict the results of insulin tolerance tests performed after administration of 
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FIGURE 4. Effect of carbutamide on hyperglycemia produced by adrenalin in a norma 
su hject . 
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FIGURE 5. Effect of carbulamide (BZ-55) on an insulin tolerance Lest in a normal 
subject. 
tolbutamide for 4 or 5 days, respectively. Again, no potentiation of insulin 
activity is demonstrated. 
In addition, in 3 of our diabetic patients in whom the drugs did not produce 
a lowering of blood sugar, there was no difference in insulin requirement 
whether the diabetes was controlled with insulin plus sulfonylurea or with 
insulin alone. One of these 3 patients is the boy with panhypopituitarism 
and diabetes, who is very sensitive to insulin and in whom any potentiation 
of insulin activity should have been very easily observed. 
That decreased function of the pituitary-adrenal system is not the mode of 
action of these compounds is indicated by the following observations: 
(1) No significant changes in renal excretion of 17-hydroxycorticoids or 
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FIGURE 6 .  Effect of tolbutamide on an insulin tolerance test in a diabetic subject, 
17-ketosteroids could be demonstrated in healthy men or in diabetic patients 
during the administration of the drugs.' 
(2) There were no significant changes in the balances of nitrogen, sodium, 
chloride, or potassium on administration of the sulfonylureas.' 
(3)  In the patient with coexisting diabetes mellitus and Addison's disease, 
administration of tolbutamide reduced the level of fasting blood sugar from 
about 150 to 110 mg. per cent, despite constant replacement therapy with 
hydrocortisone and 9a-fluorohydrocortisone. Withdrawal of the steroids 
for 2 days did not potentiate the hypoglycemic effect of tolbutamide in spite 
of the development of severe adrenal insufficiency.l 
(4) In 5 nondiabetic patients with severe adrenal insufficiency, intrave- 
nously administered sodium tolbutamide produced a similar hypoglycemic 
effect whether the patients were maintained on hydrocortisone and 9a-fluoro- 
hydrocortisone or with deoxycorticosterone alone. 
As shown in FIGURE 7, the sulfonylurea compounds do not act by blocking 
the peripheral effects of adrenocortical steroids. At a time when carbutamide 
had produced a definite hypoglycemic effect, the administration of 100 mg. of 
Prednisolone for 2 days produced the same rise in fasting blood sugar and the 
same loss of carbohydrate tolerance as when Prednisolone was given by itself. 
The sulfonylureas did not alter any of the metabolic changes produced by 
Predniso1one.l 
Carbutamide 
had no effect in the pancreatectomized patient. In  the unstable diabetic, 
The sulfonylurea compounds are not substitutes for insulin. 
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FIGURE 8. Effects of intravenous administration of insulin and of sodium tolbutamide 
on the blood levels of glucose, pyruvate, and a-ketoglutarate. 
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withdrawal of insulin and administration of either carbutamide or tolbuta- 
mide resulted in hyperglycemia, glycosuria (which a t  times equalled the intake 
of carbohydrate), ketonuria, and negative balances for nitrogen, sodium, and 
potassium.' 
FIGURE 8 shows an example of the findings obtained during 8 intravenous 
insulin tolerance tests and 7 intravenous tolbutamide tests performed in nor- 
mal subjects. Hypoglycemia induced by intravenous administration of 
insulin was associated with an initial rise in blood pyruvate. In contrast, 
when hypoglycemia was induced by intravenous administration of sodium 
tolbutamide the earliest change in levels of blood pyruvate was a decrease.2 
These differences suggest that the immediate hypoglycemia induced by 
administration of insulin on the one hand, and of tolbutzmide on the other, 
occurs via different mechanisms.2 
During oral administration of tolbutamide it was noted that, upon acidifi- 
cation of the urine to pH 5.2 or below, a precipitate appeared. At pH 3 pre- 
cipitation was fairly complete. Subsequently, a crystalline compound was 
isolated with a melting point different from that of tolbutamide. In coopera- 
tion with Struck, Wright, and Johnson of The Upjohn Laboratories, this uri- 
nary excretion product of tolbutamide has been identified as a carboxylic acid 
derived by oxidation of the methyl group linked to the aromatic ring (FIGURE 
When tolbutamide was administered to normal subjects a t  a level of 3.0 to 
6.0 gm./day, 70 to 80 per cent was excreted in the urine as this excretory 
product. When 3 to 4 gm./day was administered orally to diabetic subjects, 
excretion as the metabolite ranged between 24 and 67 per cent. This material 
is very likely the principal excretion product of tolbutamide in the human.l 
Intravenous administration of the pure tolbutamide excretion product as 
the sodium salt to 4 normal subjects and 1 diabetic patient in a dosage of 1 to 
3 gm. failed to elicit any blood-sugar-lowering effect. Oral administration 
of 6 gm. of the excretion product daily for 3 days in 4 divided doses to a normal 
subject likewise failed to influence the level of fasting blood sugar.] 
Sumvmry arid Cnvtclusion 
The data indicate that the sulfonylurea compounds do not (1) suppress the 
pituitary-adrenal system, (2) antagonize the peripheral effects of adrenal cor- 
9).3 
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ticoids, ( 3 )  block the hyperglycemic effects of glucagon and adrenalin, (4) 
potentiate the activity of exogenous insulin, and that (5) they are not insulin 
substitutes. Thus, the blood-sugar-lowering property of these compounds is 
achieved via another mechanism. 
The contrasting initial changes in blood pyruvate level associated with 
hypoglycemia induced by insulin and tolbutamide, respectively, suggest that 
the sulfonylureas produce acute hypoglycemia by a mechanism other than the 
rapid release of endogenous insulin. 
When tolbutamide is administered, a carboxylic acid derivative of this 
compound is excreted in urine as a major excretory product. 
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